Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma
- 1 July 2002
- journal article
- clinical trial
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 16 (5), 337-345
- https://doi.org/10.1007/bf02988618
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphomaCancer, 2001
- The impact of FDG positron emission tomography imaging on the management of lymphomas.The British Journal of Radiology, 2000
- 18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CTLeukemia & Lymphoma, 2000
- Whole-body 18F-FDG PET for the evaluation of patients with Hodgkinʼs disease and non-Hodgkinʼs lymphomaNuclear Medicine Communications, 1999
- Extranodal malignant lymphoma: detection with FDG PET versus CT.Radiology, 1998
- Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.Radiology, 1997
- Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.Radiology, 1994
- Ga-67 SPECT before and after treatment of lymphoma.Radiology, 1990
- Lymphoma: evaluation with Ga-67 SPECT.Radiology, 1987
- High-dose gallium imaging in lymphomaAmerican Journal Of Medicine, 1983